Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Jeremiah A Wala; Glenn J Hanna

doi:10.1016/j.hoc.2023.05.009

Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Hematol Oncol Clin North Am. 2023 Dec;37(6):1149-1168. doi: 10.1016/j.hoc.2023.05.009. Epub 2023 Jun 21.

Authors

Jeremiah A Wala¹, Glenn J Hanna²

Affiliations

¹ Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building 2nd Floor, Room 2-140, Boston, MA 02215, USA.
² Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building 2nd Floor, Room 2-140, Boston, MA 02215, USA. Electronic address: glenn_hanna@dfci.harvard.edu.

PMID: 37353377
DOI: 10.1016/j.hoc.2023.05.009

Abstract

We review chimeric antigen receptor (CAR) T-cell therapy for solid tumors. We discuss patient selection factors and aspects of clinical management. We describe challenges including physical and molecular barriers to trafficking CAR-Ts, an immunosuppressive tumor microenvironment, and difficulty finding cell surface target antigens. The application of new approaches in synthetic biology and cellular engineering toward solid tumor CAR-Ts is described. Finally, we summarize reported and ongoing clinical trials of CAR-T therapies for select disease sites such as head and neck (including thyroid cancer), lung, central nervous system (glioblastoma, neuroblastoma, glioma), sarcoma, genitourinary (prostate, renal, bladder, kidney), breast and ovarian cancer.

Keywords: Antigen selection; Cellular engineering; Chimeric antigen receptor; Clinical trials; Solid tumors; Tumor microenvironment.

Publication types

Review